Claims

1. A combination therapy composition comprising a therapeutically effective amount of lamellar bodies capable of disrupting microbial quorum sensing and at least a first non-lamellar body antimicrobial active agent, for use in the treatment of a microbial infection wherein the antimicrobial agent is an antibiotic.

2. Use of a combination therapy composition comprising a therapeutically effective amount of lamellar bodies capable of disrupting microbial quorum sensing and at least a first non-lamellar body antimicrobial active agent in the manufacture of a medicament for the treatment of a microbial infection, wherein the antimicrobial active agent is an antibiotic.

3. The use of a composition comprising a therapeutically effective amount of lamellar bodies capable of disrupting microbial quorum sensing and at least a first non-lamellar body antimicrobial active agent in the manufacture of a medicament for the treatment of a microbial infection, wherein the antimicrobial active agent is an antibiotic as claimed in claim 2, wherein the microbial infection is an infection of the lung or the eye.

4. The use of a composition comprising a therapeutically effective amount of lamellar bodies capable of disrupting microbial quorum sensing and at least a first non-lamellar body antimicrobial active agent in the manufacture of a medicament for the treatment of a microbial infection, wherein the antimicrobial active agent is an antibiotic as claimed in claim 2, wherein antibiotic is to be provided to a site of microbial infection by a different route to that of the lamellar bodies.

5. The use of a composition comprising a therapeutically effective amount of lamellar bodies capable of disrupting microbial quorum sensing and at least a first non-lamellar body antimicrobial active agent in the manufacture of a medicament for the treatment of a microbial infection, wherein the antimicrobial active agent is an antibiotic as claimed in claim 2, wherein the microbial infection is an infection of the lung or airways wherein the antibiotic is to be provided intravenously and the lamellar bodies are to be provided intranasally.

6. The use of a composition comprising a therapeutically effective amount of lamellar bodies capable of disrupting microbial quorum sensing and at least a first non-lamellar body antimicrobial active agent in the manufacture of a medicament for the treatment of a microbial infection, wherein the antimicrobial active agent is an antibiotic as claimed in claim 2, wherein the antibiotic and the lamellar bodies are to be provided in combination separately, sequentially or simultaneously.

7. The use of a composition comprising a therapeutically effective amount of lamellar bodies capable of disrupting microbial quorum sensing and at least a first non-lamellar body antimicrobial active agent in the manufacture of a medicament for the treatment of a microbial infection, wherein the antimicrobial agent is an antibiotic as claimed in claim 2, wherein the microbial infection is a bacterial infection.

8. The use of a composition comprising a therapeutically effective amount of lamellar bodies capable of disrupting microbial quorum sensing and at least a first non-lamellar body antimicrobial active agent in the manufacture of a medicament for the treatment of a microbial infection, wherein the antimicrobial agent is an antibiotic of claim 7, wherein the bacterial infection is selected from the group consisting of *Pseudomonas, Burkholderia* and *Staphylococcus* spp.

9. A combination therapy composition of claim 1 or a composition comprising a therapeutically effective amount of lamellar bodies capable of disrupting microbial quorum sensing and at least a first non-lamellar body antimicrobial active agent in the manufacture of a medicament for the treatment of a microbial infection, wherein the antimicrobial active agent is an antibiotic as claimed in any one of claims 2 to 8 wherein the lamellar bodies comprise phosphatidylcholine, sphingomyelin, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl inositol and cholesterol.

10. A combination therapy composition of claim 1 or a composition comprising a therapeutically effective amount of lamellar bodies capable of disrupting microbial quorum sensing and at least a first non-lamellar body antimicrobial active agent in the manufacture of a medicament for the treatment of a microbial infection, wherein the antimicrobial active agent is an antibiotic as claimed in any one of claims 2 to 8 wherein the lamellar bodies comprise in the range 44-70% phosphatidylcholine, in the range 15-23% sphingomyelin, in the range 6- 10% phosphatidyl ethanolamine,

in the range 2-6% phosphatidyl serine, in the range 2-4% phosphatidyl inositol and in the range 4-12% cholesterol byweight.

11.A combination therapy composition of claim 1, or a composition comprising a therapeutically effective amount of lamellar bodies capable of disrupting microbial quorum sensing and at least a first non-lamellar body antimicrobial active agent in the manufacture of a medicament for the treatment of a microbial infection, wherein the antimicrobial active agent is an antibiotic as claimed in any one of claims 2 to 8 to disrupt microbial quorum sensing and microbial biofilm formation wherein the microbial biofilm is formed by a microbe selected from the group comprising bacteria, viruses, fungi, yeasts and protozoa.

12. A combination therapy composition of claim 1, or a composition comprising a therapeutically effective amount of lamellar bodies capable of disrupting microbial quorum sensing and at least a first non-lamellar body antimicrobial active agent in the manufacture of a medicament for the treatment of a microbial infection, wherein the antimicrobial active agent is an antibiotic as claimed in any one of claims 2 to 8 to disrupt microbial quorum sensing and microbial biofilm formation wherein the microbial infection is an implant-associated and/or a catheter- associated and/or an indwelling medical device-associated infection.

13. A combination therapy composition of claim 1 or a composition comprising a therapeutically effective amount of lamellar bodies capable of disrupting microbial quorum sensing and at least a first non-lamellar body antimicrobial active agent in the manufacture of a medicament for the treatment of a microbial infection, wherein the antimicrobial active agent is an antibiotic as claimed in any one of claims 2 to 8 wherein an antimicrobial active agent used in combination with a lamellar body is an antibiotic selected from the group comprising piperacillin, aztreonam, meropenem, gentamycin, tobramycin, erythromycin, tazocin and ciprofloxacin, ceftazidime or combinations thereof.